# Nuveen Churchill Direct Lending Corp.: financial statements, quarterly

NCDL · NYSE · CIK 1737924 · [Other](/sectors/other.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ncdl.md) · [Financials](/companies/ncdl/financials.md) · [Filings](/companies/ncdl/filings.md) · [Insiders](/companies/ncdl/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ncdl/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net income | $m | [20.1](/filings/0001628280-24-045921.md) | [28.8 d](/filings/0001737924-26-000014.md) | [30.0](/filings/0001628280-25-023397.md) | [20.2](/filings/0001628280-25-038050.md) | [36.6](/filings/0001737924-25-000013.md) | [29.5 d](/filings/0001737924-26-000014.md) | [15.0](/filings/0001737924-26-000045.md) | [16.0](/filings/0001737924-26-000084.md) | [18.7](/filings/0001737924-25-000013.md) | [15.9 d](/filings/0001737924-26-000014.md) | [8.7](/filings/0001737924-26-000045.md) | [3.6](/filings/0001737924-26-000084.md) |
| Diluted EPS | $ per share | [0.62](/filings/0001628280-24-045921.md) | not reported | [0.56](/filings/0001628280-25-023397.md) | [0.57](/filings/0001628280-25-038050.md) | [0.58](/filings/0001737924-25-000013.md) | not reported | [0.53](/filings/0001628280-25-023397.md) | [0.46](/filings/0001628280-25-038050.md) | [0.43](/filings/0001737924-25-000013.md) | not reported | not reported | not reported |
| Basic EPS | $ per share | [0.62](/filings/0001628280-24-045921.md) | not reported | [0.56](/filings/0001628280-25-023397.md) | [0.57](/filings/0001628280-25-038050.md) | [0.58](/filings/0001737924-25-000013.md) | not reported | [0.53](/filings/0001628280-25-023397.md) | [0.46](/filings/0001628280-25-038050.md) | [0.43](/filings/0001737924-25-000013.md) | not reported | not reported | not reported |

- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [36.0](/filings/0001628280-23-035545.md) | [67.4](/filings/0001628280-25-008382.md) | [64.1](/filings/0001628280-24-021951.md) | [71.0](/filings/0001628280-24-035331.md) | [69.3](/filings/0001628280-24-045921.md) | [43.3](/filings/0001628280-25-038050.md) | [49.2](/filings/0001628280-25-023397.md) | [44.0](/filings/0001628280-25-038050.md) | [4.3](/filings/0001737924-25-000013.md) | [8.6](/filings/0001737924-26-000084.md) | [15.3](/filings/0001737924-26-000045.md) | [5.0](/filings/0001737924-26-000084.md) |
| Total assets | $m | [1,539](/filings/0001628280-23-035545.md) | [1,731](/filings/0001628280-25-008382.md) | [1,875](/filings/0001628280-24-021951.md) | [2,083](/filings/0001628280-24-035331.md) | [2,140](/filings/0001628280-24-045921.md) | [2,144](/filings/0001737924-26-000014.md) | [2,173](/filings/0001628280-25-023397.md) | [2,074](/filings/0001628280-25-038050.md) | [2,042](/filings/0001737924-25-000013.md) | [2,054](/filings/0001737924-26-000084.md) | [2,049](/filings/0001737924-26-000045.md) | [1,988](/filings/0001737924-26-000084.md) |
| Total liabilities | $m | [900](/filings/0001628280-23-035545.md) | [983](/filings/0001628280-25-008382.md) | [877](/filings/0001628280-24-021951.md) | [1,097](/filings/0001628280-24-035331.md) | [1,150](/filings/0001628280-24-045921.md) | [1,173](/filings/0001737924-26-000014.md) | [1,253](/filings/0001628280-25-023397.md) | [1,187](/filings/0001628280-25-038050.md) | [1,161](/filings/0001737924-25-000013.md) | [1,179](/filings/0001737924-26-000084.md) | [1,185](/filings/0001737924-26-000045.md) | [1,139](/filings/0001737924-26-000084.md) |
| Long-term debt | $m | [867](/filings/0001628280-23-035545.md) | [952](/filings/0001628280-25-008382.md) | [826](/filings/0001628280-24-021951.md) | [1,029](/filings/0001628280-24-035331.md) | [1,102](/filings/0001628280-24-045921.md) | [1,115](/filings/0001737924-26-000014.md) | [1,202](/filings/0001628280-25-023397.md) | [1,114](/filings/0001628280-25-038050.md) | [1,104](/filings/0001737924-25-000013.md) | [1,114](/filings/0001737924-26-000084.md) | [1,139](/filings/0001737924-26-000045.md) | [1,094](/filings/0001737924-26-000084.md) |
| Shareholders' equity | $m | [639](/filings/0001628280-24-045921.md) | [748](/filings/0001737924-26-000014.md) | [998](/filings/0001628280-25-038050.md) | [986](/filings/0001737924-25-000013.md) | [991](/filings/0001737924-25-000013.md) | [970](/filings/0001737924-26-000084.md) | [920](/filings/0001737924-26-000084.md) | [888](/filings/0001737924-26-000084.md) | [881](/filings/0001737924-25-000013.md) | [875](/filings/0001737924-26-000084.md) | [864](/filings/0001737924-26-000084.md) | [849](/filings/0001737924-26-000084.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(114) d](/filings/0001628280-24-045921.md) | [(135) d](/filings/0001737924-26-000014.md) | [(97.6)](/filings/0001628280-25-023397.md) | [(169) d](/filings/0001628280-25-038050.md) | [(42.3) d](/filings/0001737924-25-000013.md) | [12.0 d](/filings/0001737924-26-000014.md) | [(8.8)](/filings/0001737924-26-000045.md) | [137 d](/filings/0001737924-26-000084.md) | [37.3 d](/filings/0001737924-25-000013.md) | [28.6 d](/filings/0001737924-26-000014.md) | [(13.7)](/filings/0001737924-26-000045.md) | [61.0 d](/filings/0001737924-26-000084.md) |
| Dividends paid | $m | [14.8 d](/filings/0001628280-24-045921.md) | [16.7 d](/filings/0001737924-26-000014.md) | [19.3](/filings/0001628280-25-023397.md) | [21.5 d](/filings/0001628280-25-038050.md) | [26.5 d](/filings/0001737924-25-000013.md) | [27.9 d](/filings/0001737924-26-000014.md) | [29.5](/filings/0001737924-26-000045.md) | [28.3 d](/filings/0001737924-26-000084.md) | [22.3 d](/filings/0001737924-25-000013.md) | [22.2 d](/filings/0001737924-26-000014.md) | [22.2](/filings/0001737924-26-000045.md) | [19.8 d](/filings/0001737924-26-000084.md) |
| Share repurchases | $m | [0.0 d](/filings/0001628280-24-045921.md) | [0.0 d](/filings/0001737924-26-000014.md) | [0.0](/filings/0001628280-25-023397.md) | [5.1 d](/filings/0001628280-25-038050.md) | [5.9 d](/filings/0001737924-25-000013.md) | [22.5 d](/filings/0001737924-26-000014.md) | [37.1](/filings/0001737924-26-000045.md) | [26.0 d](/filings/0001737924-26-000084.md) | [2.7 d](/filings/0001737924-25-000013.md) | [0.0 d](/filings/0001737924-26-000014.md) | [0.0](/filings/0001737924-26-000045.md) | [0.0 d](/filings/0001737924-26-000084.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | period not labelled (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | billions of shares | [24.5](/filings/0001628280-23-035545.md) | [28.7](/filings/0001628280-24-021951.md) | [0.0](/filings/0001628280-24-035331.md) | [0.0](/filings/0001628280-24-045921.md) | [0.1](/filings/0001628280-25-023397.md) | [0.1](/filings/0001628280-25-038050.md) | [0.1](/filings/0001737924-25-000013.md) | [0.1](/filings/0001737924-26-000045.md) | [0.1](/filings/0001737924-26-000084.md) | [0.0](/filings/0001737924-25-000013.md) | [0.0](/filings/0001737924-26-000045.md) | [0.0](/filings/0001737924-26-000084.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 49,387,065 at 2026-08-05, from the cover of the [10-Q filed 2026-08-06](/filings/0001737924-26-000084.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.